Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).

被引：1
|
作者：
Rini, Brian I.
Escudier, Bernard
Murphy, Danielle
Wang, Panpan
Tarazi, Jamal Christo
Motzer, Robert J.
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Univ Paris Saclay, Gustave Roussy, Med Oncol, Villejuif, France
[3] Pfizer Oncol, La Jolla, CA USA
[4] Pfizer Oncol, Shanghai, Peoples R China
[5] Pfizer Oncol, San Diego, CA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.614
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614
引用
收藏
页数：3
相关论文
共 50 条
  • [21] WITNESS: Real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline
    Thiery-Vuillemin, A.
    Albiges, L.
    Escudier, B.
    Narciso, B.
    Bigot, P.
    Eymard, J-C.
    Calcagno, F.
    Schlurmann, F.
    Chehimi, M.
    Barthomeuf, J.
    Quentric, C.
    Vano, Y.
    Barthelemy, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S697 - S697
  • [22] An observational multicenter French study on unanswered questions in patients with advanced renal cell carcinoma (aRCC) treated with cabozantinib: OCTOPUS
    Thibault, Constance
    Mourey, Loic
    Pasquier, David
    Bernhard, Jean-Christophe
    Boissier, Marion
    Perrot, Valerie
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 430 - 430
  • [23] Association of race with clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs)
    Choi, Yujin
    Yildirim, Ahmet
    Wei, Mengting
    Liu, Yuan
    Goswamy, Rohit Vivek
    Brown, Jacqueline T.
    Nazha, Bassel
    Martini, Dylan J.
    Hartman, Caitlin
    McClintock, Greta Russler
    Zhuang, Tony
    Kissick, Haydn
    Harris, Wayne B.
    Carthon, Bradley Curtis
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Avelumab plus axitinib (A plus Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial
    Oya, M.
    Motzer, R. J.
    Choueiri, T. K.
    Haanen, J. B. A. G.
    Eto, M.
    Uemura, H.
    Venugopal, B.
    Rini, B. I.
    Miyake, H.
    Albiges, L.
    Schmidinger, M.
    Tomita, Y.
    Umeyama, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1517 - S1518
  • [25] APPLICATION OF A MACHINE LEARNING MODEL TO PREDICT SURVIVAL OUTCOMES FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (ARCC) TREATED WITH NIVOLUMAB
    Gupta, Alind
    Arora, Paul
    Brenner, Darren
    Edmonson-Jones, Mark
    Parkhomenko, Elena
    Stevens, Warren
    Wagner, Samuel
    Borrill, John
    Wu, Elise
    MEDICAL DECISION MAKING, 2020, 40 (01) : E267 - E268
  • [26] Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)
    Panian, Justine
    Zhong, Caiwei
    Choi, Sharon
    Quinn, Roxanne
    Ferrier, Evan
    Saad, Eddy
    Saliby, Renee Maria
    Malvar, Carmel
    Pal, Sumanta
    Ebrahimi, Hedyeh
    Tran, Ben
    Jude, Evon
    Lalani, Aly-Khan
    Suarez, Cristina
    De Velasco, Guillermo
    Kanesvaran, Ravindran
    Zarba, Martin
    Chehade, Razane El Hajj
    Choueiri, Toni K.
    Heng, Daniel
    McKay, Rana
    ONCOLOGIST, 2024, 29 : S23 - S23
  • [27] Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma
    Yamamoto, Yoshiaki
    Otori, Toru
    Inoue, Ryo
    Yano, Seiji
    Hirata, Hiroshi
    Matsumoto, Hiroaki
    Matsuyama, Kenji
    Matsuyama, Hideyasu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (02): : 256 - 263
  • [28] Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.
    Bello, Carlo
    Brar, Satjit
    Masters, Joanna C.
    Khandelwal, Akash
    Novakovic, Ana M.
    Ruiz-Garcia, Ana
    Hibma, Jennifer
    CANCER RESEARCH, 2021, 81 (13)
  • [29] JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Choueiri, Toni K.
    Rini, Brian I.
    Cosgriff, Thomas
    Miyake, Hideaki
    Vogelzang, Nicholas J.
    Kannourakis, George
    Mariani, Mariangela
    Chiruzzi, Chiara
    Albiges, Laurence
    Haanen, John B.
    Larkin, James
    Atkins, Michael B.
    Schmidinger, Manuela
    Magazzu, Domenico
    Di Pietro, Alessandra
    Motzer, Robert J.
    BJU INTERNATIONAL, 2016, 118 : 29 - 30
  • [30] Development and internal validation of a prognostic nomogram for overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib (PAZ)
    Kattan, Michael W.
    Chakrabarti, Debasis
    Bhatt, Kamalnayan
    Mehmud, Faisal
    Sternberg, Cora N.
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345